NCT00638937 2018-08-29AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination ChemotherapyNational Cancer Institute (NCI)Phase 2 Completed37 enrolled 13 charts
NCT00475956 2010-04-15Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed40 enrolled